China SXT Pharmaceuticals Inc (SXTC) Stock Analysis
Verdict: AVOID
Severe revenue collapse and heavy cash burn outweigh balance sheet cash, driving relentless equity dilution and downside risk.
Investment score: 17/100
Analysis as of
Is China SXT Pharmaceuticals Inc stock worth reviewing? AI model thesis
The model views SXTC as a high-risk micro-cap suffering from severe top-line contraction and cash burn, warranting an Avoid recommendation.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 10/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
China SXT Pharmaceuticals Inc opportunities and risks
What speaks for SXTC
- Substantial Stated Cash Position
What speaks against SXTC
- Persistent Operating Losses and Cash Burn
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SXTC | n/a | 0.3x | 3.2x | 44.4% | -290.7% | -771.6% |
| ZYBT | n/a | 4.4x | n/a | 8.3% | -89.0% | 11.1% |
| CPHI | n/a | 6.6x | n/a | -9.3% | -114.3% | -0.8% |
| UPC | n/a | 0.1x | 11.8x | 35.9% | -10.9% | -465.9% |
| CHME | n/a | 0.0x | n/a | 0.0% | 0.0% | 0.0% |
| LTUS | n/a | 0.0x | n/a | 0.0% | 0.0% | 0.0% |
| Peer median | n/a | 0.1x | n/a | 0.0% | -10.9% | 0.0% |
Frequently asked questions about China SXT Pharmaceuticals Inc (SXTC)
Is SXTC stock a good investment?
The cached TradeMates AI model rates China SXT Pharmaceuticals Inc as AVOID with an investment score of 17/100. The model views SXTC as a high-risk micro-cap suffering from severe top-line contraction and cash burn, warranting an Avoid recommendation. This is algorithmic model output, not personal investment advice.
Is SXTC stock a buy?
The TradeMates model verdict for SXTC is AVOID with an investment score of 17/100. Treat this as a model signal to review, not a personal buy recommendation.